I. COMMENCED TRADING IN OCTOBER

Company (Symbol)

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Post-Offering Market Cap (M)

INITIAL OFFERINGS

There were no initial public offerings conducted in October.

Total: $0M

Number of IPOs in October: 0

Average value of October IPOs: $0M

Number of IPOs in 2002: 4

Total raised in IPOs in 2002: $464.7M*

Average value of IPOs in 2002: $116.19M*

* Figures include an overallotment option exercised in January as part of a 2001 IPO.

Figures do not include an IPO conducted in June by YM BioSciences Inc. because the shares were privately placed.

FOLLOW-ON OFFERINGS

Company (Symbol)^#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)^%

Lead, Other Underwriters

Gross (M)

Post-Offering Market Cap (M)^@

NPS Pharmaceuticals Inc. (NPSP)¹

1/7/02

10/25

4.6S

$23.95

35

Morgan Stanley & Co.
Merrill Lynch & Co.
Salomon Smith Barney

$110.17

$838.25

Tularik Inc. (TLRK)²

8/14/01

10/18

4S

$6.80

49.2

Goldman, Sachs & Co.

$27.2

$334.56

OVERALLOTMENT OPTIONS EXERCISED

Telik Inc. (TELK)³

6/3/02

10/4

0.975S

$11.50

35.5

UBS Warburg (lead)
Wachovia Securities
Legg Mason Wood Walker
Needham & Company

$11.2

$408.25

Total: $148.57M

Number of follow-on offerings in October: 2

Average value of October follow-ons: $74.29M

Number of follow-on offerings in 2002: 20

Total raised in follow-ons in 2002: $866.35M

Average value of follow-ons in 2002: $43.32M

Notes:

^# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

^% This column reflects the shares outstanding following the offering, when disclosed.

@ Market capitalization calculated is based on the offering price.

¹ NPS' offering includes the underwriters overallotment option for 600,000 shares.

² Tularik priced 4M shares to raise $27.2M.

³ Telik's underwriters exercised their overallotment option, adding another $11.2M to the company's public offering completed in September.

II. FILED AND PENDING

Company (Symbol/Proposed Symbol)^#*

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)^%

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

DiaDexus Inc. (DDXS)¹

11/20/00

7S

$12-14

31.1

Lehman Brothers
CIBC World Markets
Robertson Stephens
Fidelity Capital Markets

$91

MitoKor Inc. (MITO)²

3/8/02

N/A

N/A

N/A

RBC Capital Markets
Lazard Freres
Legg Mason Wood Walker
Gerard Klauer Mattison

$60

Novirio Pharmaceuticals Ltd. (IDIX)³

4/12/02

N/A

N/A

N/A

Goldman Sachs (co-lead)
Banc of America Securities (co-lead)
JP Morgan Securities
U.S. Bancorp Piper Jaffray

$115

Stem Genetics Inc. (N/A)⁴

7/18/02

1.5S

$7

32.3

Self-underwritten

$10.5

ViaCell Inc. (VIAC)⁵

1/30/02

N/A

N/A

N/A

UBS Warburg
Banc of America Securities
U.S. Bancorp Piper Jaffray

$115

FOLLOW-ON OFFERINGS

Advanced Tissue Sciences Inc. (ATIS)⁶

6/12/02

10S

$1.07

N/A

N/A

$10.7

Antigenics Inc. (AGEN)⁷

6/13/02

N/A

N/A

33.1

N/A

$100

Aphton Corp. (APHT)⁸

7/8/02

5S

$6.50

25.1

N/A

$32.5

Ariad Pharmaceuticals Inc. (ARIA)⁹

1/9/02

3S

$5.28

35.4

N/A

$15.84

Biomira Inc. (Canada; BIOM; TSE:BRA)¹⁰

5/2/02

N/A

N/A

53.4

N/A

C$150
(US$97.84)

Celgene Corp. (CELG)¹¹

12/21/01

N/A

N/A

75.6

N/A

$500

Cell Pathways Inc. (CLPA)¹²

2/7/01

N/A

N/A

N/A

N/A

$25

Cepheid Inc. (CPHD)¹³

12/21/01

N/A

N/A

26.56

N/A

$35

Cerus Corp. (CERS)¹⁴

8/13/01

N/A

N/A

15.7

N/A

$300

CollaGenex Pharmaceuticals Inc. (CGPI)¹⁵

10/26/01

0.965S

$8.01

N/A

Kingsbridge Capital Prentice Securities

$7.7

Cytogen Corp. (CYTO)¹⁶

10/26/01

10S

$2.50

79.8

N/A

$25

Dyax Corp. (DYAX)¹⁷

4/25/02

5S

$3.66

19.6

N/A

$18.3

EntreMed Inc. (ENMD)¹⁸

5/10/02

N/A

N/A

N/A

N/A

$50

Epimmune Inc. (EPMN)¹⁹

10/25/02

7.25S

$1.32

19.4

Punk Ziegel & Co. (placement agent)

$9.57

Exelixis Inc. (EXEL)²⁰

7/30/01

N/A

N/A

49.2

N/A

$150

Genaera Corp. (GENR)²¹

11/21/01

N/A

N/A

38.9

N/A

$50

Genaissance Pharmaceuticals Inc. (GNSC)²²

10/18/01

N/A

N/A

22.8

N/A

$35

Geron Corp. (GERN)²³

1/30/02

N/A

N/A

N/A

N/A

$150

Hollis-Eden Pharmaceuticals Inc. (HEPH)²⁴

2/26/02

3S

$8.71

N/A

N/A

$26.13

InSite Vision Inc. (AMEX:ISV)²⁵

2/2/01

N/A

N/A

N/A

Ladenburg Thalmann (placement agent)

$40

Myriad Genetics Inc. (MYGN)²⁶

11/9/01

N/A

N/A

N/A

N/A

$250

NeoTherapeutics Inc. (NEOT)²⁷

1/3/01

N/A

N/A

26.9

N/A

$50

Neurogen Corp. (NRGN)²⁸

8/16/02

N/A

N/A

N/A

N/A

$75

Northwest Biotherapeutics Inc. (NWBT)²⁹

6/4/02

11S

$3.77

17

C.E. Unterberg, Towbin

$41.5

Pharmos Corp. (PARS)³⁰

2/4/02

N/A

N/A

56.6

N/A

$25

SciClone Pharmaceuticals Inc. (SCLN)³¹

11/6/01

N/A

N/A

N/A

N/A

$20

StemCells Inc. (STEM)³²

3/8/02

15S

$2.52

25.8

N/A

$37.8

Targeted Genetics Corp. (TGEN)³³

12/13/01

8.84S

$2.57

N/A

N/A

$22.72

Triangle Pharmaceuticals Inc. (VIRS)³⁴

9/25

N/A

N/A

N/A

N/A

$80

Tularik Inc. (TLRK)³⁵

8/14/01

N/A

N/A

49.2

N/A

$250

III. WITHDRAWN AND POSTPONED

Company (Symbol/Proposed Symbol)^#*

Date Filed/Date Pulled

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

Corcept Therapeutics Inc. (CORT)³⁶

12/21/01
10/3/02

4S

$14-16

23.9

U.S. Bancorp Piper Jaffray (co-lead)
CIBC World Markets (co-lead)
Thomas Weisel Partners

$60

Protarga Inc. (PRTG)³⁷

12/12/01
10/3/02

N/A

N/A

N/A

UBS Warburg (co-lead)
U.S. Bancorp Piper Jaffray (co-lead)

$75

Notes:

^# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

^* Stock symbols for companies seeking to complete IPOs are proposed.

^% This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; TSE = Toronto Stock Exchange

¹ DiaDexus' IPO value, $91M, is based on the sale of 7M shares at $13 each, the midpoint of the expected price range. The underwriters have an overallotment option on 1.05M shares.

² MitoKor filed for an IPO to raise $60M.

³ Novirio filed for an IPO to raise $115M.

⁴ Stem Genetics filed for an IPO to raise $10.5M. It intends to go public on the Over-the-Counter Bulletin Board, but did not specify a proposed symbol in its SEC filing.

⁵ ViaCell filed for a $115M IPO. No further details were disclosed.

⁶ Advanced Tissue filed a shelf registration statement with the SEC to issue up to 10M shares of its common stock. The value, $10.7M, is based on the June 12 closing stock price of $1.07.

⁷ Antigenics filed a shelf registration statement covering the issuance of common and preferred stock, as well as secured and unsecured debt securities, up to $60M. It also had a previous registration with $40M in securities remaining.

⁸ Aphton filed a shelf registration statement to sell up to 5M shares at a maximum amount of $6.50 per share. The company privately placed 2.5M shares worth $5M in September.

⁹ Ariad filed a shelf registration statement to sell up to 3M shares. At the Jan. 8 closing stock price, it would raise $15.84M.

¹⁰ Biomira filed for a $150M shelf prospectus in Canada.

¹¹ Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M.

¹² Cell Pathways filed a shelf registration statement for the sale of $25M in common stock. The company privately placed $4.4M in shares in September.

¹³ Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants.

¹⁴ Cerus filed to sell up to $300M of common stock and debt in a shelf offering.

¹⁵ The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01. CollaGenex privately placed 119,335 shares in May, raising $1M. It placed 32,187 shares in June, raising $266,667.

¹⁶ Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration statement. It privately placed 3M shares in January, and another 4.17M shares in June.

¹⁷ Dyax filed a shelf registration statement to sell up to 5M shares. The value, $18.3M, is based on the April 24 closing stock price, $3.66.

¹⁸ EntreMed filed a $50M shelf registration statement, allowing it to offer securities from time to time in the form of common stock, preferred stock or warrants to purchase securities.

¹⁹ Epimmune filed to sell 7.25M shares at $1.32 per share for $9.57M.

²⁰ Exelixis filed a shelf registration statement to sell up to $150M in common stock.

²¹ Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock. It privately placed $16.5M in shares in April.

²² Genaissance filed a shelf registration statement to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M.

²³ Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants.

²⁴ Hollis-Eden filed a shelf registration statement to sell up to 3M shares and warrants from time to time. The value is based on the proposed maximum offering price.

²⁵ InSite filed a shelf registration statement in February 2001 to sell $40M in stock.

²⁶ Myriad filed a shelf registration statement for the sale of up to $250M of various types of securities.

²⁷ NeoTherapeutics filed a shelf registration statement covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. In May 2001, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M. In November, it placed 950,000 shares, raising $3.8M. In December, it placed 0.77M shares, raising $2.95M. In March 2002, it raised $8.05M in a private placement. In June, it raised $1.66M in a private placement. In July, it raised $1.1M in a private placement.

²⁸ Neurogen filed for a $75M universal shelf registration statement.

²⁹ Northwest expects to offer 11M shares as part of a lock-up agreement with the underwriter from the company's December initial public offering. The value, $41.5M, is based on the June 3 closing stock price of $3.77.

³⁰ Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants.

³¹ SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering. SciClone privately placed $10.62M in shares in June.

³² StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed.

³³ Targeted Genetics filed a shelf registration statement for the sale of up to about 8.84M shares of common stock. The value is based on the Jan. 22 closing stock price of $2.57.

³⁴ Triangle filed a shelf registration with the SEC to sell up to $80M in common and preferred stock.

³⁵ Tularik filed to sell up to $250M in common stock and debt securities. It raised $27.2M in October with an offering of 4M shares.

³⁶ Corcept's offering was for 4.5M shares, 4M sold by the company and 500,000 sold by a selling stockholder. The company withdrew the IPO in October due to market conditions.

³⁷ Protarga filed for an IPO with hopes of raising $75M. It withdrew the offering in October due to market conditions.